Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Abstract B054: Systemic Therapy and Outcomes in Patients with Intermediate or High-Risk Solitary Fibrous Tumor
Lin, Miranda, Siontis, Brittany, Robinson, S I, Okuno, Scott, Ho, Thanh, Siontis, Brittany L. , Robinson, Steven I. , Ho, Thanh

Mayo Clinic

Cancer Research | July 18, 2026 | Volume: 86 | Issue: 14_Supplement | Pages: B054-B054

10.1158/1538-7445.rareca26-b054 Get It

Abstract Background: Solitary fibrous tumors (SFT) make up less than 5% of sarcomas. The Demicco model stratifies risk of metastasis based on age, tumor size, mitotic count, and necrosis. Patients (pts) with relapsed disease have limited options. We evaluated outcomes of systemic therapies (tx) to treat SFT. Methods: A retrospective analysis was performed of pts with intermediate-to-high risk SFT confirmed by soft tissue pathologists at a multi-site health system from 1999 – 2024. Demographics, tx, and pt outcomes were analyzed. Radiographic response was abstracted from documentation by treating provider. Results: Sixty pts had intermediate-to-high risk SFT, of which 21 pts received systemic tx. Of these, 12 were male, median age at diagnosis 62.8 years (41.0 – 82.7 yrs). Tumors originated from chest (11, 52.4%), abdomen (5, 23.8%), pelvis (4, 19.0%), and skull (1, 4.8%). All pts had surgery for primary tumor, median size 16.0 cm (7.8 – 43.0), and 14 (66.7%) had surgery at relapse. Eight pts (38.1%) had perioperative radiation therapy (RT); 12 (57.1%) had palliative RT. Five (23.8%) had ablation. Of the 21 pts, 2 (9.5%) had perioperative chemotherapy (chemo). Twenty pts (95.2%) received median 2 lines (1 – 6) of palliative systemic tx (1 pt did not pursue any). One pt had partial response on dacarbazine, otherwise best clinical response was stable disease (SD, 53.1% vascular endothelial growth factor inhibitors (VEGFi), 40% chemo) or disease progression (PD). Most pts received VEGFi: 11 pts had sunitinib (median 3.1 months, range 1.0 – 10.6 mo), 11 pts had pazopanib (4.1 mo, 0.1 – 38.7), and 10 pts had temozolomide/bevacizumab (5.6 mo, 1.0 – 15.8). VEGFi was dose reduced or held in 59.4% . Discontinuation due to toxicity occurred in 34.4% of pts treated with VEGFi vs 26.7% of pts treated with chemo. Five pts received liposomal doxorubicin (median 4.8 mo, range 3.5 – 11.3). Four pts had doxorubicin with dacarbazine, ifosfamide or olaratumab (2.8 mo, 0.7 – 8.5). Two pts received dacarbazine (1.9 and 9.6 mo, respectively), and 2 pts received gemcitabine/docetaxel (0.9 and 4 mo). Eribulin and trabectedin (1 pt, respectively) were used for less than 1 mo. Tx was held or dose reduced for 1 pt on doxorubicin/dacarbazine and 1 pt on gemcitabine/docetaxel. Three pts had immunotherapy (IO, 2 pts pembrolizumab, 1 pt nivolumab/ipilimumab) and stopped for PD (2 pts) or toxicity (1 pt) after 2 mo or less. Two pts participated in clinical trials. Median time from primary surgery to relapse was 2.0 yrs (0.0 – 12.3). Sixteen pts died (76.2%), 14 from SFT. Median time from relapse to death or last contact was 4.1 yrs (0.5 – 14.7). Median overall survival from diagnosis to death/last contact was 6.6 yrs (0.6 – 27.0). Conclusion: Perioperative chemo was rarely used to treat intermediate-to-high risk SFT. For relapse, VEGFi use was more common than chemo, with more pts achieving SD and receiving longer duration of tx. VEGFi had greater toxicity and subsequent discontinuation. No benefit was observed in few pts who received IO. Clinical trial participation was uncommon. Citation Format: Miranda Lin, Brittany Siontis, Steven Robinson, Scott Okuno, Thanh Ho. Systemic Therapy and Outcomes in Patients with Intermediate or High-Risk Solitary Fibrous Tumor [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Breaking Barriers in the Fight against Rare Cancers; 2026 Jul 18-20; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(14_Suppl):Abstract nr B054.
Glioblastoma Subtypes Exhibit Distinct Migration Mechanics and Immune Responses
Shamsan, Ghaidan A. , Liu, Chao J. , Braman, Brooke C. , Li, Ruyi , Rathe, Susan K. , Sarver, Aaron L. , Ghaderi, Nima , McMahon, Mariah , Klank, Rebecca L. , McFarren, S Joseph. , Masopust, David , Clark, H. Brent , Rosenfeld, Steven S. , Largaespada, David A. , Tschida, Barbara R , McFarren, S Joseph , Rosato, Pamela C , Masopust, David , Sarkaria, Jann N , Clark, H Brent , Rosenfeld, Steven S , Largaespada, David A. , Odde, David J , Shamsan, Ghaidan A , Liu, Chao J. , Rathe, Susan K. , Sarkaria, Jann N.

Mayo Clinic

Cancer Research Communications | July 14, 2026 | Volume: 6 | Issue: 8 | Pages: 1898-1915

10.1158/2767-9764.crc-25-0579 | PMID 42447444 Get It

Abstract Glioblastoma (GBM) remains a deadly cancer driven in part by invasion of tumor cells into the brain. Transcriptomic analyses have identified distinct molecular subtypes, but mechanistic differences that account for clinical differences are not clear. In this study, we show that, as predicted by the motor-clutch model of cell migration, mesenchymal glioma cells are more spread, generate larger traction forces, and migrate faster in brain tissue compared with proneural cells. Despite their rapid migration and comparable proliferation rates in vitro, mice with mesenchymal tumors survive longer than those with proneural tumors. This improved survival correlated with an immune response in mesenchymal tumors, including T cell–mediated. Consistently, inducing mesenchymal tumors in immunodeficient mice resulted in shorter survival, supporting a protective immune role in mesenchymal tumors. Thus, mesenchymal tumors have aggressive migration but are immunologically “hot,” which suppresses net proliferation. These two features counteract each other and may explain the lack of a strong survival difference between subtypes clinically, while also opening up new opportunities for subtype-specific therapies. Significance: This study highlights new mechanical and immunologic insights into GBM molecular subtypes using an integrated modeling–genome engineering strategy, which can potentially facilitate GBM subtype-specific therapeutic strategies.
Impact of faculty and resident gender on milestone evaluations in anesthesiology residency: a retrospective analysis
Martin, Yvette N. , Rose, Steven H., Gali, Bhargavi , Martin McGrew, Yvette , Schroeder, Darrell R.

Mayo Clinic

Medical Education Online | July 10, 2026 | Volume: 31 | Issue: 1 | Pages: No page available

10.1080/10872981.2026.2688660 | PMID 42429203 Get It

First-in-Human Safety and Feasibility of Nodal and Pedal MR Lymphangiography with Gadopiclenol
Thompson, Scott M. , Collins, Jeremy D. , Bendel, Emily C. , Reisenauer, Christopher J., Jundt, Michael C., Yalҫin, Müge, Favazza, Christopher , Lu, Aiming , McDonald, Robert J. , Williamson, Eric E. , Stinson, Eric G. , In, MyungHo, Favazza, Christopher P , Messina, Steven A , Collins, Jeremy , Williamson, Eric , Thompson, Scott , Bendel, Emily , In, Myung-Ho , Jundt, Michael C., In, Myung‐Ho , Messina, Steven A.

Mayo Clinic

Radiology: Cardiothoracic Imaging | July 2, 2026 | Volume: 8 | Issue: 4 | Pages: No page available

10.1148/ryct.260067 | PMID 42390347 Get It

Dynamic gadopiclenol-enhanced nodal and pedal MR lymphangiography was safe, with no adverse events, and feasible for imaging peripheral and central conducting lymphatic anatomy.
Microtubule Acetylation Regulates the Malignant Phenotype of Glioblastoma and is a Promising Therapeutic Target
Dovas, Athanassios, Bhattacharya, Santanu, Kulkarni, Tanmay, Amini, Misha, Haddock, Ashley, Nagaiah, Naveen KH, Mukhopadhyay, Debrabrata, Suarez-Meade, Paola, Quinones-Hinojosa, Alfredo, Canoll, Peter, Kenchappa, Rajappa, Rosenfeld, Steven S. , Rosenfeld, Steven S , Zarco, Natanael , Bhattacharya, Santanu , Kulkarni, Tanmay, Liu, Yi , Haddock, Ashley , Nagaiah, Naveen K H, Suárez-Meade, Paola , Quiñones‐Hinojosa, Alfredo , Miller, Courtney A. , Kamenecka, Theodore M. , Canoll, Peter, Kenchappa, Rajappa S.

Mayo Clinic

No container title available | June 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.15.732342 Get It

ABSTRACT Glioblastoma (GBM) is universally lethal despite decades of research to find effective treatments. This highlights the need to identify druggable targets essential for sustaining the malignant phenotype but dispensable for normal tissue. We propose that the enzyme α-tubulin acetyl transferase ( ATAT1 ) meets these criteria. ATAT1 acetylates α-tubulin at lysine 40, which increases microtubule stability and promotes microtubule-based transport. While ATAT1 knockout mice have only a very mild phenotype, ATAT1 suppression in GBM has multiple therapeutic effects by reducing tumor invasion, proliferation, and therapeutic resistance. These translate not only into improved survival with ATAT1 targeting by itself, but also into synergy when ATAT1 deletion is combined with FDA approved therapies. This study strongly supports our conclusion that ATAT1 is a promising therapeutic target in GBM.
Multi-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma
Garcia, David M., Lin, Wan‐Hsin , Wickland, Daniel P. , Jessen, Erik , Middlebrooks, Erik H. , Haydu, Lauren E. , Brooks, Mieu , Feathers, Ryan W. , Kinsella, Lindsey , Sereduk, Chris , Rosenfeld, Steven S. , Chaichana, Kaisorn L. , Anastasiadis, Panos Z. , Quiñones‐Hinojosa, Alfredo , Jessen, Erik , Tran, Nhan L , Chaichana, Kaisorn L , Anastasiadis, P Z , Quinones-Hinojosa, Alfredo , Middlebrooks, Erik H , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | June 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noag139 | PMID 42296327 Get It

Abstract Background Glioblastoma (GBM) remains a devastating cancer with limited treatment options, largely due to its heterogeneity. While supramaximal resection has recently provided survival benefits, therapeutic profiling of different tumor compartments, particularly its infiltrative edge remains largely unexplored. Methods Here, we leveraged magnetic resonance imaging (MRI)-guided multi-sampling, collecting 2 cores and 2 margins per case, to query GBM heterogeneity. Whole-exome and RNA-seq with drug testing in two patient-derived 3D models were used to reveal similarities and differences in genomic and transcriptomic makeups, cellular compositions, and drug responses across cores and margins. Bioinformatics interrogations further identified response biomarkers. Results Mutation analysis showed that oncogenes exhibited a higher degree of spatial heterogeneity than tumor suppressor genes, regardless of MRI status. While the mesenchymal transcriptional subtype with extracellular matrix remodeling, stress response, and immune programs were preferentially enriched in enhancing cores, proneural tumors with neurological processes favored non-enhancing margins. Using a 15-drug GBM-targeted panel, ERK (ulixertinib) and PI3K pathway (paxalisib, CC-115) inhibitors showed preferential efficacy in enhancing cores and non-enhancing margins, respectively. The anti-apoptosis, pan-Bcl2 agent navitoclax and the epigenetic drug trotabresib represented the most effective, tumor-wide monotherapies. Importantly, drug combinations generally outperformed single agents across all regions. Conclusions This work demonstrates the regional heterogeneity of therapeutic vulnerabilities in GBM ex vivo, showing various drugs with tumor-wide or MRI-enhancement informed activity. These findings offer preclinical bases of numerous monotherapies and drug combinations for future clinical trial design.
Reflections on rural community characteristics by an outreach, recruitment, and engagement team
Vassilaki, Maria , Smith, Steven M. , Loftin, Tasha M. , Mohamed, Essa A. , Rethemeier, Nick , Coburn, Ryan P , Graff‐Radford, Jonathan , Petersen, Ronald C. , Boeve, Bradley F. , Lunde, Angela , Lunde, Angela M , Boeve, Brad , Coburn, Ryan P

Mayo Clinic

Journal of Alzheimer’s Disease | June 9, 2026 | Volume: 112 | Issue: 3 | Pages: 1175-1181

10.1177/13872877261454612 | PMID 42261694 Get It

Rural populations are underrepresented in cognitive impairment research and have limited resources for education about brain and cognitive health, Alzheimer's disease and related dementias, or caregiving. As our Outreach, Recruitment, and Engagement team aimed to expand activities into more rural communities, we also wanted to better understand the characteristics of the communities surrounding our center and gain insight into the social exposome of the areas. The goal of the manuscript is to reflect on our experience and share measures that were useful in this effort, which can be further enriched and adjusted by other outreach teams.
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
Riedel, Richard F. , Riedel, Richard F , Dickson, Mark A. , Ballman, Karla V. , Weiss, Mia C. , Attia, Steven , Pollack, Seth M. , Choy, Edwin , Wagner, Andrew J. , Wilky, Breelyn A , Davis, Lara E. , Koff, Andrew, Tap, William D.

Mayo Clinic

Journal of Clinical Oncology | June 3, 2026 | Volume: 44 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2026.44.17_suppl.lba2 Get It

LBA2 Background: Dedifferentiated liposarcoma (DDLS) remains a difficult disease to treat with limited systemic therapy options. Approved drugs offer modest benefit such as trabectedin (median progression-free survival [mPFS] 2.2 months [m]) or eribulin (mPFS 2.0m). The Cyclin-dependent kinase 4 (CDK4) oncogene is ubiquitously amplified in DDLS and is a rational therapeutic target. In single-arm phase 2 studies, treatment with selective CDK4 inhibitors resulted in mPFS 4.2m with palbociclib and mPFS 7.7m with abemaciclib. We hypothesized that treatment with abemaciclib would improve PFS compared to placebo in patients with recurrent or metastatic DDLS. Methods: SARC041 was a phase 3 randomized double-blind study of abemaciclib versus placebo. The study was open at 9 academic medical centers in the USA. Eligible patients (pts) had recurrent or metastatic DDLS (purely well-differentiated liposarcoma excluded), progression of disease by RECIST 1.1 in the 6 months prior to study entry, any number of prior systemic therapies, and adequate organ function and performance status. Pts were stratified by prior lines of therapy (0 vs 1 or more) and randomized 1:1 between abemaciclib 200 mg PO twice a day or matching placebo. Scans were every 6 weeks (every 12 weeks after week 36) and pts with progression of disease on placebo could cross over to open label abemaciclib. The primary endpoint was PFS. The design provided 80% power with two-sided 10% significance level to detect a hazard ratio of 0.6 by log-rank test. Secondary endpoints were overall response rate (ORR), PFS and response rate after crossover, and overall survival (OS). Data cutoff was March 1, 2026. Results: In total, 108 pts were randomized to receive abemaciclib (n = 54) or placebo (n = 54). Demographic/baseline characteristics were generally similar across treatment arms. Abemaciclib demonstrated a statistically significant improvement in PFS at 9.67m vs placebo at 1.52m (hazard ratio [HR] 0.39; 95% confidence interval [CI], 0.25–0.59; p < 0.001). ORR was 9.3% for abemaciclib vs 0% for placebo (p = 0.057). mOS was not reached with abemaciclib vs 25.45m with placebo (HR 0.55; 95% CI, 0.28–1.07; p = 0.077). mPFS after crossover from placebo to abemaciclib was 3.44m (95% CI 2.66, 6.84). ORR after crossover was 4.3% (95% CI 0.53%, 15%). mOS after crossover was 24.03m (95% CI: 11.7, NA). Grade 3 or higher adverse event rates were similar in both arms (p > 0.99). No new safety signals were observed. Conclusions: Abemaciclib demonstrated a statistically significant improvement in PFS vs placebo in pts with dedifferentiated liposarcoma, with an encouraging OS trend. These results support abemaciclib as a new treatment option for dedifferentiated liposarcoma. Clinical trial information: NCT04967521 .
Non-surgical management and outcome of 1,113 patients with stage I-II non-small cell lung cancer (NSCLC) in a 20-year cohort.
Yang, Ping, Ou, Cristina, Ernani, Vinicius , Gu, Zhong, Buras, Matthew, D’Cunha, Jonathan, Wampfler, Jason A. , Gu, Zhong, Schild, Steven E. , Sio, Terence T.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 8045-8045

10.1200/jco.2026.44.16_suppl.8045 Get It

8045 Background: Surgical resection is the primary therapy for stage I-II NSCLC but not performed in a subset of patients due to comorbidities or self-election, who instead undergo radiation with or without systemic therapy (RT±ST). Little is known about the demographic, tumoral, therapeutic, and quality-of-life (QOL) characteristics of this non-surgical group. Understanding their differences from the surgical group is essential for developing precision treatment strategies and tailored survivorship guidelines. Methods: In a prospectively enrolled (1997-2016) and followed (through 2025) cohort of 20,951 primary lung cancer patients, 6,486 (31%) had stage I-II NSCLC, including 5,359 (83%) treated surgically (Surgical) and 1,113 (17%) otherwise (Non-surgical). Preexisting diseases were grouped into cancer, lung, and other comorbidities. QOL data were available for 40% of all patients. Descriptive analysis of demographics, tumor features, treatment patterns, and QOL metrics, as well as survival analysis (median years and overall survival [OS] rates) were conducted. QOL measures, on overall and 15 symptom and functional domains, were scored 0 (worst) to 10 (best), with 1-unit difference considered clinically and statistically meaningful. Results: At time of diagnosis, compared to the Surgical, the Non-surgical patients were older (median 73 v 68 years), more likely to have smoked cigarettes (91% v 83%), squamous cell and unspecified NSCLC (53% v 28%), stage IIB (19% v 12%), and preexisting lung comorbidities (71% v 58%). Non-surgical patients more frequently received RT±ST than the Surgical (70% v 21%) and had shorter median survival (2.5 v 7.8) years. Within the Non-surgical, 28% had no cancer treatment (No-Tx), 44% RT-only, 7% ST-only, and 19% both (RT+ST); their respective median diagnosis ages were 74, 76, 68, 70 years; median survival were 1.7, 2.7, 2.2, 3.2 years; 5-year OS (95%CI) at 25% (21-31), 25% (21-29), 26% (17-38), 30% (25-37); and 10-year OS at 9% (7-14), 7% (5-10), 10% (5-21), 9% (6-14), respectively. RT-only group had highest rates of comorbidities (37-84%) and the No-Tx the lowest (31-66%). Although the overall QOL scored the same for all groups, RT-only patients reported the worst scores on multiple symptoms burden, and the No-Tx reported the least pain and lung cancer symptoms but the worst on mental well-being and social activities. Conclusions: Non-surgically managed stage I-II NSCLC cases present clinically distinct patients with the shortest median survival in No-Tx group and highest 5-year survival in RT+ST. RT-only patients were oldest, had the most comorbidities, and reported the worst symptom burdens. These differences highlight the need for more in-depth analyses and studies (considering age, histology, comorbidity, QOL, etc.) to support tailored therapeutic strategies and survivorship care for patients who decline or are not suitable for surgery.
A deep learning approach to quantify tumor microenvironment features associated with postoperative ctDNA status and outcomes in a phase III FOLFOX-based adjuvant colon cancer trial (N0147; Alliance).
Sinicrope, Frank A., Shi, Qian, Segovia, Diana I. , Hardin, Aaron, Alberts, Steven R., Pai, Rish, Sinicrope, Frank A. , Shi, Qian , Hardin, Aaron , Rich, Thereasa A. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 3525-3525

10.1200/jco.2026.44.16_suppl.3525 Get It

3525 Background: Tumor microenvironment (TME) features of colorectal cancer (CRC) may influence detection of circulating tumor DNA (ctDNA) and further refine prognosis. We applied a deep learning histopathologic algorithm to quantify TME features in stage III colon cancers and evaluated their association with postoperative ctDNA status among participants in a phase III FOLFOX-based adjuvant trial (NCCTG N0147). Methods: QuantCRC (Aiforia Technologies) was applied to digitized hematoxylin and eosin-stained whole-slide images of stage III colon adenocarcinomas to extract quantitative histopathologic features. Among cases where data met quality control (N=1817), associations between 15 distinct pathologist-defined features and clinical outcomes—time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS)—were evaluated, stratified by postoperative ctDNA status assessed by a tissue-free assay (Guardant Reveal). Relationships were analyzed using univariate and multivariable Cox proportional hazards models that were adjusted for clinicopathologic and molecular features ( KRAS , BRAF V600E , MMR status). Interaction testing was performed. Results: We found statistically significant quantitative differences for histopathological features by ctDNA status. Features associated with ctDNA positivity(+) included lymphovascular invasion (LVI), and increased %high grade, %tumor budding, %necrosis, and %stroma. ctDNA+ cases had lower %inflammatory stroma and fewer %signet ring cells (all p< 0.006). Multivariable analyses, irrespective of ctDNA status, identified %tumor budding, %mucin, %signet ring cells, %inflammatory tumor bed, and %inflammatory stroma as significantly associated with adverse outcomes (TTR, DFS, OS). Within ctDNA+ cases, higher %immature tumor bed was associated with adverse outcome for all 3 variables. Among ctDNA-negative cases, significantly poorer outcomes (TTR, DFS, OS) were observed for tumors with lower tumor infiltrating lymphocyte (TIL) density and reduced %necrosis. After adjustment, significant interactions with ctDNA status were observed for LVI (p< 0.006) and %signet ring cells (p< 0.035) across all outcome variables, for %necrosis with DFS, OS (p<0.040), and for TILs with TTR (p<0.015). Analysis is ongoing for ctDNA tumor fraction as well as tumor genotyping data (739 genes; Guardant360). Conclusions: QuantCRC identifies TME features associated with postoperative ctDNA status that enable risk-stratification within ctDNA groups. Among ctDNA-negative patients, reduced intratumoral TIL density and reduced tumor necrosis identify high-risk subgroups with inferior clinical outcomes, and may have clinical utility.